Table 2.

Vaccine efficacy (Poisson method) against first/only herpes zoster episode during the whole study per underlying disease (modified total vaccinated cohort)

	RZV				Placebo
Type	N	n	Cumulative follow-up† (years)	Number per 1000 person-years	N	n	Cumulative follow-up† (years)	Number per 1000 person-years	Vaccine efficacy % (95% CI)	p-Value‡
Multiple myeloma	472	22	907.2	24.2	465	69	786.7	87.7	72.35 (54.76–83.71)	<0.0001
Non-Hodgkin B-cell lymphoma	237	19	438.5	43.3	244	45	410.6	109.6	60.46 (31.02–78.16)	0.0006
Non-Hodgkin T-cell lymphoma	43	1	78.9	12.7	40	5	69.2	72.3	82.45 (−56.81–99.63)	0.1633
Hodgkin lymphoma	74	5	136.9	36.5	60	7	110.2	63.5	42.50 (−110.44–85.61)	0.5028
Acute myeloid leukemia	20	0	32.2	0.0	16	3	19.8	151.4	100 (−48.86–100)	0.1105
Solid malignancies and autoimmune diseases	24	2	39.4	50.8	26	6	35.4	169.4	70.00 (−67.75–97.04)	0.2253

CI = confidence interval; N = number of participants included in each group; n = number of participants having at least one confirmed herpes zoster episode; RZV = adjuvanted recombinant zoster vaccine.

^†Censored at the first occurrence of a confirmed herpes zoster episode and at the occurrence of treatment for relapse.

^‡p-value = Two-sided exact p-value conditional to number of cases.